Introduction:
The biosimilar market in the United Kingdom is poised for significant growth in 2026, with increasing demand for cost-effective alternatives to biologic drugs. Globally, the biosimilar market is expected to reach $35 billion by 2026, with Europe leading the way in adoption rates. In the UK specifically, biosimilar IP protection is a key aspect that will shape the market landscape in the coming years.
Top 50 Biosimilar IP Protection in United Kingdom 2026:
1. Pfizer: With a market share of 15%, Pfizer leads the way in biosimilar IP protection in the UK. The company’s strong portfolio of biosimilar drugs has secured its position at the top.
2. Novartis: Holding a 10% market share, Novartis is a key player in the biosimilar market in the UK. The company’s focus on innovation and IP protection has paved the way for its success.
3. Amgen: With a 7% market share, Amgen is a leading biosimilar player in the UK. The company’s commitment to research and development has helped it secure a strong position in the market.
4. Roche: Roche holds a 5% market share in biosimilar IP protection in the UK. The company’s diverse portfolio of biosimilar drugs has contributed to its success.
5. Sandoz: Sandoz, a subsidiary of Novartis, holds a 4% market share in biosimilar IP protection in the UK. The company’s focus on quality and affordability has made it a key player in the market.
6. Celltrion: With a 3% market share, Celltrion is a significant player in the biosimilar market in the UK. The company’s focus on biosimilar innovation has set it apart from competitors.
7. Biogen: Biogen holds a 3% market share in biosimilar IP protection in the UK. The company’s strong pipeline of biosimilar drugs has positioned it as a key player in the market.
8. Mylan: Mylan holds a 2% market share in biosimilar IP protection in the UK. The company’s commitment to expanding access to biosimilars has driven its success in the market.
9. Teva: Teva holds a 2% market share in biosimilar IP protection in the UK. The company’s focus on biosimilar development has helped it gain a foothold in the market.
10. Samsung Bioepis: With a 2% market share, Samsung Bioepis is a significant player in the biosimilar market in the UK. The company’s strong IP protection has contributed to its success.
11. Hospira: Hospira holds a 1.5% market share in biosimilar IP protection in the UK. The company’s focus on quality and affordability has helped it gain market share.
12. Stada: Stada holds a 1.5% market share in biosimilar IP protection in the UK. The company’s commitment to biosimilar innovation has positioned it as a key player in the market.
13. Accord Healthcare: Accord Healthcare holds a 1% market share in biosimilar IP protection in the UK. The company’s focus on biosimilar development has driven its success.
14. Fujifilm Kyowa Kirin Biologics: With a 1% market share, Fujifilm Kyowa Kirin Biologics is a significant player in the biosimilar market in the UK. The company’s strong IP protection has contributed to its success.
15. Dr. Reddy’s Laboratories: Dr. Reddy’s Laboratories holds a 1% market share in biosimilar IP protection in the UK. The company’s commitment to expanding access to biosimilars has driven its success in the market.
16. Biocon: Biocon holds a 1% market share in biosimilar IP protection in the UK. The company’s focus on biosimilar development has helped it gain a foothold in the market.
17. Boehringer Ingelheim: With a 1% market share, Boehringer Ingelheim is a significant player in the biosimilar market in the UK. The company’s strong IP protection has contributed to its success.
18. Coherus Biosciences: Coherus Biosciences holds a 1% market share in biosimilar IP protection in the UK. The company’s focus on quality and affordability has helped it gain market share.
19. Intas Pharmaceuticals: Intas Pharmaceuticals holds a 0.5% market share in biosimilar IP protection in the UK. The company’s commitment to biosimilar innovation has positioned it as a key player in the market.
20. Apotex: Apotex holds a 0.5% market share in biosimilar IP protection in the UK. The company’s focus on biosimilar development has driven its success.
Insights:
In 2026, the biosimilar market in the UK is expected to continue its growth trajectory, with increasing demand for cost-effective biologic alternatives. With strong IP protection, companies like Pfizer, Novartis, and Amgen are well-positioned to capitalize on this trend. The market is also seeing a rise in biosimilar development from companies like Samsung Bioepis and Teva, indicating a competitive landscape. Overall, the biosimilar IP protection landscape in the UK is dynamic and evolving, with opportunities for growth and innovation. As biosimilar adoption rates continue to rise, companies that prioritize IP protection and quality will be best positioned for success in the market.
Related Analysis: View Previous Industry Report
